Personalized assessment and treatment of depression

Current Opinion in Psychology

Volumn 4, Issue , 2015, Pages 67-74

  Fisher, Aaron J ^a   Bosley, Hannah G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937828781     PISSN: 2352250X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copsyc.2015.03.031     Document Type: Review

References (47)

1. Westen D., Morrison K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol 2001, 69:875-899.
2. Hasin D.S., Goodwin R.D., Stinson F.S., Grant B.F. Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Arch Gen Psychiatry 2005, 62:1097-1106.
3. Berlim M.T., Fleck M.P., Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med 2008, 40:149-159.
4. Insel T.R. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry 2009, 66:128-133.
5. Molenaar P.C.M. A manifesto on psychology as idiographic science: bringing the person back into scientific psychology, this time forever. Measurement 2004, 2:201-218.
6. Barlow D.H., Nock M.K. Why can't we be more idiographic in our research?. Perspect Psychol Sci 2009, 4:19-21.
7. Insel T.R. From inconvenient truth to urgent opportunity. Observer 2013, 26.
8. Hamburg M.A., Collins F.S. The path to personalized medicine. N Engl J Med 2010, 363:301-304.
9. Cuijpers P., Reynolds C.F., Donker T., Li J., Andersson G., Beekman A. Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depress Anxiety 2012, 29:855-864.
10. Wray N.R., Pergadia M.L., Blackwood D.H.R., Penninx B.W.J.H., Gordon S.D., Nyholt D.R., Ripke S., MacIntyre D.J., McGhee K.A., Maclean A.W., et al. Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned. Mol Psychiatry 2012, 17:36-48.
11. Mitjans M., Serretti A., Fabbri C., Gastó C., Catalán R., Fañanás L., Arias B. Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology 2013, 227:509-519.
12. Adkins D.E., Daw J.K., McClay J.L., van den Oord E.J.C.G. The influence of five monoamine genes on trajectories of depressive symptoms across adolescence and young adulthood. Dev Psychopathol 2012, 24:267-285.
13. Yeh Y.-W., Chen C.-J., Jang F.-L., Kuo S.C., Chen C.Y., Liang C.S., Ho P.S., Yen C.H., Shyu J.F., Wan F.J., et al. SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population. J Psychiatric Res 2015, 61:33-39.
14. Domschke K. Clinical and molecular genetics of psychotic depression. Schizophr Bull 2013, 39:766-775.
15. Mamdani F., Berlim M.T., Beaulieu M.-M., Turecki G. Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder. World J Biol Psychiatry 2013, 15:135-144.
16. Menke A. Gene expression: biomarker of antidepressant therapy?. Int Rev Psychiatry 2013, 25:579-591.
17. Zajkowska Z.E., Englund A., Zunszain P.A. Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. Pharmacogenomics 2014, 15:687-698.
18. Preskorn S.H., Kane C.P., Lobello K., Nichols A.I., Fayyad R., Buckley G., Focht K., Guico-Pabia C.J. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 2013, 74:614-621.
19. Cattaneo A., Gennarelli M., Uher R., Breen G., Farmer A., Aitchison K.J., Craig I.W., Anacker C., Zunsztain P.A., McGuffin P., Pariante C.M. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013, 38:377-385.
20. Eley T.C., Hudson J.L., Creswell C., Tropeano M., Lester K.J., Cooper P., Farmer A., Lewis C.M., Lyneham H.J., Rapee R.M., et al. Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatry 2012, 17:236-237.
21. Eley T.C. The future of therapygenetics: where will studies predicting psychological treatment response from genomic markers lead?. Depress Anxiety 2014, 31:617-620.
22. Bockting C.L.H., Mocking R.J., Lok A., Koeter M.W.J., Schene A.H. Therapygenetics: the 5HTTLPR as a biomarker for response to psychological therapy[quest]. Mol Psychiatry 2013, 18:744-745.
23. Lester K.J., Eley T.C. Therapygenetics: using genetic markers to predict response to psychological treatment for mood and anxiety disorders. Biol Mood Anxiety Dis 2013, 3:4.
24. Adkins D.E., Souza R.P., Åberg K., Clark S.L., McClay J.L., Sullivan P.F., van den Oord E.J. Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D. PLoS ONE 2013, 8:e55239.
25. Arns M., Drinkenburg W.H., Fitzgerald P.B., Kenemans J.L. Neurophysiological predictors of non-response to rTMS in depression. Brain Stimul 2012, 5:569-576.
26. Fox M.D., Liu H., Pascual-Leone A. Identification of reproducible individualized targets for treatment of depression with TMS based on intrinsic connectivity. Neuroimage 2013, 66:151-160.
27. Takizawa R., Fukuda M., Kawasaki S., Kasai K., Mimura M., Pu S., Noda T., Niwa S., Okazaki Y. Neuroimaging-aided differential diagnosis of the depressive state. Neuroimage 2014, 85:498-507.
28. Hill C.E., Chui H., Baumann E. Revisiting and reenvisioning the outcome problem in psychotherapy: an argument to include individualized and qualitative measurement. Psychotherapy 2013, 50:68-76.
29. Trujols J., Portella M.J., Pérez V. Toward a genuinely patient-centered metric of depression recovery: one step further. JAMA Psychiatry 2013, 70:1375.
30. Lindhiem O., Kolko D.J., Cheng Y. Predicting psychotherapy benefit: a probabilistic and individualized approach. Behav Therapy 2012, 43:381-392.
31. Huang S.H., LePendu P., Iyer S.V., Tai-Seale M., Carrell D., Shah N.H. Toward personalizing treatment for depression: predicting diagnosis and severity. J Am Med Inform Assoc 2014, 21:1069-1075.
32. DeRubeis R.J., Cohen Z.D., Forand N.R., Fournier J.C., Gelfand L.A., Lorenzo-Luaces L. The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS ONE 2014, 9:e83875.
33. Paul G.L. Strategy of outcome research in psychotherapy. J Consult Psychology 1967, 31:109.
34. Wallace M.L., Frank E., Kraemer H.C. A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 2013, 70:1241-1247.
35. Lutz W., Stulz N., Kock K. Patterns of early change and their relationship to outcome and follow-up among patients with major depressive disorders. J Affect Dis 2009, 118:60-68.
36. Stulz N., Lutz W., Leach C., Lucock M., Barkham M. Shapes of early change in psychotherapy under routine outpatient conditions. J Consult Clin Psychol 2007, 75:864-874.
37. Schumm J.A., Walter K.H., Chard K.M. Latent class differences explain variability in PTSD symptom changes during cognitive processing therapy for veterans. Psychol Trauma Theory Res Pract Policy 2013, 5:536-544.
38. Siddique J., Chung J.Y., Brown C.H., Miranda J. Comparative effectiveness of medication versus cognitive-behavioral therapy in a randomized controlled trial of low-income young minority women with depression. J Consult Clin Psychol 2012, 80:995-1006.
39. Thibodeau M.A., Quilty L.C., De Fruyt F., De Bolle M., Rouillon F., Bagby R.M. Latent classes of nonresponders, rapid responders, and gradual responders in depressed outpatients receiving antidepressant medication and psychotherapy. Depress Anxiety 2014, 32:213-220.
40. Grosse Holtforth M., Altenstein D., Krieger T., Flückiger C., Wright A.G.C., Caspar F. Interpersonal differentiation within depression diagnosis: relating interpersonal subgroups to symptom load and the quality of the early therapeutic alliance. Psychother Res 2013, 24:429-441.
41. Cain N.M., Ansell E.B., Wright A.G.C., Hopwood C.J., Thomas K.M., Pinto A., Markowitz J.C., Sanislow C.A., Zanarini M.C., Shea M.T., et al. Interpersonal pathoplasticity in the course of major depression. J Consult Clin Psychol 2012, 80:78-86.
42. Wittink M., Morales K., Cary M., Gallo J., Bartels S. Towards personalizing treatment for depression. Patient 2013, 6:35-43.
43. Gaudiano B.A., Nowlan K., Hughes J.A., Miller I.W. Gender differences in hospitalised patients' perceived reasons for their depression. J Psychiatr Intensive Care 2014, 10:23-32.
44. Bellon J., Conejo-Ceron S., Moreno-Peral P., King M., Nazareth I., Martín-Pérez C., Fernández-Alonso C., Ballesta-Rodríguez M.I., Fernández A., Aiarzaguena J.M., et al. Preventing the onset of major depression based on the level and profile of risk of primary care attendees: protocol of a cluster randomised trial (the predictD-CCRT study). BMC Psychiatry 2013, 13:171.
45. Bellon J.A., Moreno-Peral P., Moreno-Kustner B., Motrico E., Aiarzagüena J.M., Fernández A., Fernández-Alonso C., Montón-Franco C., Rodríguez-Bayón A., Ballesta-Rodríguez M.I., et al. Patients' opinions about knowing their risk for depression and what to do about it. The predictD-qualitative study. PLoS ONE 2014, 9:e92008.
46. Saveanu R., Etkin A., Duchemin A.-M., Goldstein-Piekarski A., Gyurak A., Debattista C., Schatzberg A.F., Sood S., Day C.V., Palmer D.M., et al. The International Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res 2015, 61:1-12.
47. Fisher A.J. Toward a dynamic model of psychological assessment: implications for personalized care. J Consult Clin Psychol 2015, May 25, Advance online publication. 10.1037/ccp0000026.